Claudia Garulli

Corrigendum to “Does severe obesity define a threshold over which robotic sentinel lymph node mapping outperforms laparoscopic mapping in endometrial cancer?” [Surgical Oncology 68 (2026) 102535]

Lorenzo Novara, Luca Pace, Maria Pascotto, Carola Minella et autres

it (code pays fourni par la source)

Clinical and ultrasonographic features preceding a difficult-to-treat phenotype in psoriatic arthritis: a retrospective real-world exploratory cohort study

Elisa Bellis, Mariele Gatto, Claudio Cruciani, Federico Favaro et autres

Objectives: To explore clinical and ultrasonographic features preceding the development of a difficult-to-treat (D2T) phenotype in a real-world cohort of patients with psoriatic arthritis (PsA). Materials and methods: In this retrospective cohort study, consecutive PsA patients (January 2020-September 2024) were included. D2T …

it (code pays fourni par la source)

Does severe obesity define a threshold over which robotic sentinel lymph node mapping outperforms laparoscopic mapping in endometrial cancer?

Luca Novara, Luca Pace, Maria Pascotto, Carola Minella et autres

it (code pays fourni par la source)

Symptom Monitoring in Ovarian Cancer Patients Treated with PARP Inhibitors: Agreement Between Physician- and Patient-Reported Toxicities Using PRO-CTCAE

Roberta Massobrio, Daniela Attianese, Alessandra Testi, Maria Pascotto et autres

Background: Poly(ADP-ribose) polymerase inhibitor (PARPi) treatment in ovarian cancer patients after first-line chemotherapy and following the response to platinum-based chemotherapy at relapse is associated with survival benefits. Maintenance therapies can be administered over extended periods, making treatment tolerability assessment essential in optimizing …

it (code pays fourni par la source)

Flowchart for endometrial cancer classification integrating FIGO 2023 staging and ESGO/ESTRO/ESP 2025 risk categories

Luca Pace, Luca Novara, Claudia Garulli, Diletta Fumagalli et autres

it (code pays fourni par la source)

“Real-life tolerability of PARP inhibitors in ovarian cancer: agreement between physician and patient-reported toxicities using PRO-CTCAE”

Beatrice Campigotto, Roberta Massobrio, Maria Pascotto, Alessandra Testi et autres

it (code pays fourni par la source)

Real-Life Outcomes Of First Line Maintenance Treatment With Bevacizumab Or Niraparib In High-Risk, BRCA Wild-Type, HRD Negative Ovarian Cancer Patients

Roberta Massobrio, Daniela Attianese, Luca Fuso, Luca Pace et autres

it (code pays fourni par la source)